{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/a4c5de36-8260-4222-8e38-ff997dc73436/64e8d776-3df1-4864-8d98-23ed2a4400a4?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Biotech: The good times aren't over","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/61b9b44742e856e989985776/61b9b4cd24374a00129afda9.jpg?height=200","description":"Lower valuations make now a good buying opportunity for long-term growth in the biotech sector","author_name":"Investors' Chronicle"}